noom weight loss glp 1 Our GLP-1 Journey Our GLP-1 Weight Loss Journey

Some people also risk nutrient deficiencies (like B12) and pancreas issues

Pregnant/breastfeeding Type 1 diabetes mellitus Diabetes ketoacidosis Hypersensitivity to Semaglutide/Tirzepatide or any components of these medications Personal or family history of medullary thyroid carcinoma History of multiple endocrine neoplasia syndrome History of pancreatitis End stage renal disease (on dialysis) Patients with diabetic retinopathy Who IS a candidate

The FDA-approved labels for GLP-1 receptor agonists acknowledge effects on satiety but emphasize their primary metabolic actions

Obesity is the fastest-growing indication segment, driven by high-efficacy weight loss data, expanded regulatory approvals, and direct-to-consumer demand [1]

For now, semaglutide remains a proven, licensed treatment with extensive real-world data Retatrutide is still investigational